Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
RESEARCH TOOLSreports
Holding KYTX?
Track your performance easily
KYTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.30 - $35.06
Previous Close$6.6
Volume744.16K
Average Volume (3M)472.92K
Market Cap
$284.77M
Enterprise Value-$51.47M
Total Cash (Recent Filing)$346.24M
Total Debt (Recent Filing)$10.00M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 12, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.63
Shares Outstanding43,146,852
10 Day Avg. Volume286,986
30 Day Avg. Volume472,921
Standard Deviation0.21
R-Squared0.07
Alpha-0.19
Financial Highlights & Ratios
Price to Book (P/B)0.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.84
Forecast
1Y Price Target
$32.00Price Target Upside362.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Kyverna Therapeutics, Inc. News
PremiumCompany Announcements
Kyverna Therapeutics Announces Executive Leadership Changes
Bulls Say, Bears Say
Bulls Say
Clinical TrialsKYTX’s collaborator published the first clinical data to showcase the potential of KYTX’s CD19 CAR-T in multiple sclerosis (MS).
LeadershipNew CEO expected to bring commercial experience to leadership team.
Regulatory MilestonesThe FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KYTX’s KYV-101 for the treatment of stiff-person syndrome (SPS).
Bears Say
Competitive PressureKYV-101, along with other DNA-modified CAR-T therapeutics, may face tough competition from RNA-modified CAR-Ts that can be dosed multiple times and at higher aggregate dose levels per cycle.
Efficacy ConcernsLackluster KYV-101 data to date have implications for DNA-based CAR-Ts, and the ability for a low-dose, one-time DNA-modified CAR-T therapy to produce deep and durable responses in the autoimmune setting remains questionable.
Financial PerformanceKyverna reported its 2Q24 financial results, recording a net loss of $0.67 per share in 2Q24, vs. prior estimate of a net loss of $0.41 per share.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $6.30 and its highest was $35.06 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2024 which is 39 days ago.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 14, 2024. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.84 by -$0.28.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -$0.7.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,146,850 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.84. Following the earnings report the stock price went up 7.198%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Among the largest hedge funds holding Kyverna Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Kyverna Therapeutics, Inc.’s shares valued at 15M.
---
Kyverna Therapeutics, Inc. Stock Smart Score
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
---
KYTX Stock 12 Month Forecast
Average Price Target
$32.00
▲(362.43% Upside)
Technical Analysis
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-36.80%
reiterated a buy rating 2 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.80% per trade.
---